The nursery at RiverSpring Residences in the Bronx is a sunny, inviting space outfitted with a bassinet, a crib with a musical mobile, a few toys, bottles, picture books for bedtime reading and a rack of clothing in tiny sizes. The other morning, Wilma Rosa was there trying to soothe …
The number of people in the United States who develop dementia each year will double over the next 35 years to about one million annually by 2060, a new study estimates, and the number of new cases per year among Black Americans will triple. The increase will primarily be due …
The human body is an intricate system where diseases that seem unrelated at first glance can share deep-rooted connections, often through genetics. Congenital heart disease (CHD) and Alzheimer’s disease (AD) may appear worlds apart—one is a structural problem of the heart present at birth, while the other is a neurodegenerative …
Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease. But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English …
GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue …
The Food and Drug Administration approved a new Alzheimer’s treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain’s decline in patients facing the early stages of the disease. Branded as Kisunla by drugmaker Eli Lilly, donanemab’s …
